{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Genotoxic impurities", "International Conference on Harmonization (ICH)", "Process development", "Quality control", "Tecovirimat"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "38742068", "DateRevised": {"Year": "2024", "Month": "05", "Day": "15"}, "Article": {"Language": ["eng"], "ELocationID": ["e29559", "10.1016/j.heliyon.2024.e29559"], "ArticleDate": [{"Year": "2024", "Month": "05", "Day": "02"}], "Journal": {"ISSN": "2405-8440", "JournalIssue": {"Volume": "10", "Issue": "9", "PubDate": {"Year": "2024", "Month": "May", "Day": "15"}}, "Title": "Heliyon", "ISOAbbreviation": "Heliyon"}, "ArticleTitle": "Impurity study of tecovirimat.", "Pagination": {"StartPage": "e29559", "MedlinePgn": "e29559"}, "Abstract": {"AbstractText": ["This article delineates the systematic identification, synthesis, and impurity control methods used during the manufacturing process development of tecovirimat, an antiviral drug that treats monkeypox. Critical impurities were synthesized, and their chemical structure was confirmed through NMR analysis, GC, and HPLC mass spectrometry. The results established a thorough approach to identify, address, and control impurities to produce high-quality tecovirimat drug substance in accordance with International Conference on Harmonization (ICH)-compliant standards. This study is the first of its kind to evaluate both process and genotoxic impurities in tecovirimat, demonstrating effective control measures during commercial sample investigations and scaling up to a 60-kg batch size. The findings highlight the importance of critical impurity characterization and control in pharmaceutical development and production to ensure the safety and efficacy of the final product."], "CopyrightInformation": "\u00a9 2024 The Authors. Published by Elsevier Ltd."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, PR China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, PR China."}], "LastName": "Bonku", "ForeName": "Emmanuel Mintah", "Initials": "EM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, PR China."}, {"Identifier": [], "Affiliation": "State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi, Xinjiang, 830011, PR China."}], "LastName": "Qin", "ForeName": "Hongjian", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, PR China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, PR China."}], "LastName": "Odilov", "ForeName": "Abdullajon", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, PR China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, PR China."}], "LastName": "Abduahadi", "ForeName": "Safomuddin", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, PR China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, PR China."}], "LastName": "Desta Guma", "ForeName": "Samuel", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, PR China."}], "LastName": "Yang", "ForeName": "Feipu", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Vigonvita Life Science Co., Ltd., 108 Yuxin Road, Suzhou Industrial Park, Suzhou, Jiangsu, 215123, PR China."}], "LastName": "Xing", "ForeName": "Xinglong", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Vigonvita Life Science Co., Ltd., 108 Yuxin Road, Suzhou Industrial Park, Suzhou, Jiangsu, 215123, PR China."}], "LastName": "Wang", "ForeName": "Xukun", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, PR China."}, {"Identifier": [], "Affiliation": "University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, PR China."}], "LastName": "Shen", "ForeName": "Jingshan", "Initials": "J"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Heliyon", "NlmUniqueID": "101672560", "ISSNLinking": "2405-8440"}, "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Tecovirimat, SIGA  . European Medicines Agency; 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/tecovirimat-siga"}, {"Citation": "2018. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation 2021."}, {"Citation": "Hughes D.L. Review of the patent literature: synthesis and final forms of antiviral drugs tecovirimat and baloxavir marboxil. Org. Process Res. Dev. 2019;23:1298\u20131307."}, {"Citation": "Funel J.A.A.S. Industrial applications of the Diels\u2013alder reaction. Angew. Chem., Int. Ed. 2013;52(14):3822\u20133863.", "ArticleIdList": ["23447554"]}, {"Citation": "McNamara O.A., Maguire A.R. The norcaradiene-cycloheptatriene equilibrium. Tetrahedron. 2011;67(1):9\u201340."}, {"Citation": "Maier G. Das norcaradien\u2010problem. Angew. Chem. 1967;79(10):446\u2013458."}, {"Citation": "Reisman S.E., Nani R.R., Levin S. Buchner and beyond: arene cyclopropanation as applied to natural product total synthesis. Synlett. 2011;(17):2437\u20132442."}, {"Citation": "Schwiebert K.E., Stryker J.M. Transition cetal-mediated [3+ 2+ 2] allyl/alkyne cycloaddition reactions. A new reactivity pattern for the synthesis of seven-membered carbocycles. J. Am. Chem. Soc. 1995;117(31):8275\u20138276."}, {"Citation": "Etkin N., Dzwiniel T.L., Schweibert K.E., Stryker J.M. Cobalt-mediated intermolecular allyl/alkyne [3+ 2+ 2] cycloaddition reactions. A practical metal template for convergent synthesis of functionalized seven-membered rings. J. Am. Chem. Soc. 1998;120(37):9702\u20139703."}, {"Citation": "Older C.M., McDonald R., Stryker J.M. Unprecedented coordination modes and demetalation pathways for unbridged polyenyl ligands. Ruthenium \u03b7, \u03b74-cycloheptadienyl complexes from allyl/alkyne cycloaddition. J. Am. Chem. Soc. 2005;127(41):14202\u201314203.", "ArticleIdList": ["16218612"]}, {"Citation": "Tsukada N., Sakaihara Y., Inoue Y. Palladium-catalyzed cycloheptatriene formation by [3+ 2+ 2] cocyclization of 2-substituted allylic alcohols and alkynes. Tetrahedron Lett. 2007;48(23):4019\u20134021."}, {"Citation": "Kamikawa K., Shimizu Y., Matsuzaka H., Uemura M. Stereoselective [3+ 2+ 2] cycloaddition utilizing optically active binuclear Fischer carbene complexes with alkynes. J. Organomet. Chem. 2005;690(24\u201325):5922\u20135928."}, {"Citation": "Winberg W. Synthesis of cycloheptatriene. J. Org. Chem. 1959;24(2):264\u2013265."}, {"Citation": "Robinson G.C. Pyrolytic conversion of 7, 7-dichloronorcarane to cycloheptatriene. J. Org. Chem. 1964;29(11):3433\u20133434."}, {"Citation": "Parham W.S., Throckmorton J.R., Kuncl K., Dodson R.M. Reactions of enol ethers with carbenes. V. Rearrangements of dihalocyclopropanes derived from six-, seven-, and eight-membered cyclic enol Ethers1. J. Am. Chem. Soc. 1965;87(2):321\u2013328."}, {"Citation": "Jordan R., Bailey T.R., Rippin S.R., Dai D. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases. U.S. Patent. Sep 10, 2013;8 530,509 B2."}, {"Citation": "Jordan R., Bailey T.R., Rippin S.R., Dai D.U.S. Patent. Aug 12, 2014;8:802. 714 B2."}, {"Citation": "Tyavanagimatt S.R., Stone M.A.C.L., Weimers W.C., Nelson D., Bolken T.C., Hruby D.E., O'Neill M.H., Sweetapple G., McCloughan K.A. Polymorphic forms of ST-246 and methods of preparation. U.S. Patent Appl. 2011/0236434. Sep 29, 2011"}, {"Citation": "Tyavanagimatt S.R., Anderson M.A.C.L.S., Weimers W.C., Nelson D., Bolken T.C., Hruby D.E., O'Neill M.H., Sweetapple G., McCloughan K.A. Polymorphic forms of ST-246 and methods of preparation. U.S. Patent Appl. 2016/0107993 A1. Apr 21, 2016"}, {"Citation": "Tyavanagimatt S.R., Anderson M.A.C.L.S., Weimers W.C., Nelson D., Bolken T.C., Hruby D.E., O'Neill M.H., Sweetapple G., McCloughan K.A. U.S. Patent Appl. 2018/0193308. Jul 12, 2018"}, {"Citation": "Tyavanagimatt S.R., Anderson M.A.C.L.S., Weimers W.C., Nelson D., Bolken T.C., Hruby D.E., O'Neill M.H., Sweetapple G., McCloughan K.A. U.S. Patent Appl. 2018/0311213 A1. Nov 1, 2018"}, {"Citation": "Tyavanagimatt S.R., Anderson M.A.C.L.S., Weimers W.C., Nelson D., Bolken T.C., Hruby D.E., O'Neill M.H., Sweetapple G., McCloughan K.A.U.S. Aug 14, 2018. Patent 9,744,154 B2, Aug 29, 2017. B2."}, {"Citation": "Tyavanagimatt S.R., Anderson M.A.C.L.S., Weimers W.C., Nelson D., Bolken T.C., Hruby D.E., O'Neill M.H., Sweetapple G., McCloughan K.A. U.S. Patent 10,045,964 B2. Aug 14, 2018"}, {"Citation": "Tyavanagimatt S.R., Stone M.A.C.L., Weimers W.C., Nelson D., Bolken T.C., Hruby D.E., O'Neill M.H., Sweetapple G., McCloughan K.A. Polymorphic forms of ST-246 and methods of preparation. U.S. Patent 9,339,466B2. May 17, 2016"}, {"Citation": "Dong M.-x., Zhang J., Peng S.-q., Lu H., Yun L.-h., Jiang S., Dai Q.-y. Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents. Eur. J. Med. Chem. 2010;45:4096\u20134103.", "ArticleIdList": ["20598780"]}, {"Citation": "Dai Q., Dong M., Hu J. Crystal Thereof and Preparation Method Thereof. Chinese Patent Appl. CN101445478; Jun 3, 2009. Compound ST-246 containing a crystal water."}, {"Citation": "Wang H., Zhang D., Dou Y., Xu L., Guo Y., Sun Y., Bei Z., Yang Y., Dong P., Li L., Yang L. Dec 8, 2010. Preparation Method of ST-246 Stereoisomer, Chinese Patent Appl. CN101906064."}, {"Citation": "Jordan R.B.T.R., Rippin S.R. 2005. Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases; p. 56. Patent WO 2004/112718 A3."}, {"Citation": "Dai D. Methods of preparing tecovirimat. U.S. Patent. Dec 18, 2018 10,155,723 B2."}, {"Citation": "Bailey T.R., Rippin S.R., Opsitnick E., Burns C.J., Pevear D.C., Collett M.S., Rhodes G., Tophan S., Huggins J.W., Baker R.O., et al. N-(3, 3a, 4, 4a, 5, 5a, 6, 6a-octahydro-1, 3-dioxo-4, 6-ethenocycloprop[2]isoindol-2-(1 H)-yl) carboxamides: identification of novel orthopoxvirus egress inhibitors. J. Med. Chem. 2007;50(7):1442\u20131444.", "ArticleIdList": ["PMC4067006", "17335190"]}, {"Citation": "Tyavanagimatt S.R., Stone M.A.C.L., Weimers W.C., Nelson D., Bolken T.C., Hruby D.E., O'Neill M.H., Sweetapple G., McCloughan K.A. Polymorphic forms of ST-246 and methods of preparation. U.S. Patent Appl. 2011/0236434. Sep 29, 2011"}, {"Citation": "Tyavanagimatt S.R., Anderson M.A.C.L.S., Weimers W.C., Nelson D., Bolken T.C., Hruby D.E., O'Neill M.H., Sweetapple G., McCloughan K.A. Polymorphic forms of ST-246 and methods of preparation. U.S. Patent Appl. 2016/0107993 A1. Apr 21, 2016"}, {"Citation": "Tyavanagimatt S.R., Anderson M.A.C.L.S., Weimers W.C., Nelson D., Bolken T.C., Hruby D.E., O'Neill M.H., Sweetapple G., McCloughan K.A. U.S. Patent Appl. 2018/0193308. Jul 12, 2018"}, {"Citation": "Leitich J.S.G., Sprintschnik G. Verl\u00e4uft die thermische Cycloaddition von Maleins\u00e4ureanhydrid an Cycloheptatrien, 7H Benzocyclohepten und 7H-Benzocyclohepten-7, 7-dicarbonitril nach [4\u03c0+ 2\u03c0] oder [2\u03c0+ 2\u03c0+ 2\u03c0] Chem. Ber. 1986;119(5):1640\u20131660."}, {"Citation": "International conferences on harmonization of technical requirements for registration of pharmaceuticals for human use, ICH harmonized tripartite guideline, impurities in new drug substances. 2006;Q3A(R2)"}, {"Citation": "Bonku E.M., Qin H., Odilov A., Yang F., Xing X., Wang X., Shen J. Efficient large-scale process for tecovirimat via reactive distillation for the preparation of cycloheptatriene. Org. Process Res. Dev. 2023;27(11):1984\u20131991."}, {"Citation": "Elder D.P., Snodin D., Teasdale A. Control and analysis of hydrazine, hydrazides and hydrazones\u2014genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products. J. Pharmaceut. Biomed. Anal. 2011;54(5):900\u2013910.", "ArticleIdList": ["21145684"]}, {"Citation": "Ma L., Ma Y.-N., Chen Z., Jiang Y. Structural alerts of genotoxic impurities. Chinese Journal of New Drugs. 2014;23:2106\u20132111."}, {"Citation": "Benigni R., Bossa C., Tcheremenskaia O., Worth A. 2009. Development of Structural Alerts for the in Vivo Micronucleus Assay in Rodents."}, {"Citation": "Snodin D.J. Genotoxic impurities: from structural alerts to qualification. Org. Process Res. Dev. 2010;14(4):960\u2013976."}, {"Citation": "Sawatari K., Nakanishi Y., Matsushima T. Relationships between chemical structures and mutagenicity: a preliminary survey for a database of mutagenicity test results of new work place chemicals. Ind. Health. 2001;39(4):341\u2013345.", "ArticleIdList": ["11758998"]}, {"Citation": "von E Doering W., Hoffmann A.K., Hoffmann A.K. The addition of dichlorocarbene to olefins. J. Am. Chem. Soc. 1954;76(23):6162\u20136165."}, {"Citation": "Winberg H. Synthesis of cycloheptatriene. J. Org. Chem. 1959;24(2):264\u2013265."}, {"Citation": "Bhavana V., Srinivasa Rao Y. A review on analysis of genotoxic impurities. Int. J. Sci. Res. 2018;9 SR20808120645."}, {"Citation": "ICH Q3B (R2) 2006. Impurities in New Drug Products."}, {"Citation": "ICH Q3C (R6 . 2006. Impurities: Guidelines for Residual Solvents."}, {"Citation": "Ich M.7. Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit the potential carcinogenic risk. Guidance for Industry. 2014"}, {"Citation": "Nair A.S., Singh A.K., Kumar A., Kumar S., Sukumaran S., Koyiparambath V.P., Mathew B. FDA-approved trifluoromethyl group-containing Drugs: a review of 20 years. Processes. 2022;10(10):2054."}, {"Citation": "Kim E.J., Kim J.H., Kim M.S., Jeong S.H., Choi D.H. Process analytical technology tools for monitoring pharmaceutical unit operations: a control strategy for continuous process verification. Pharmaceutics. 2021;13(6):919.", "ArticleIdList": ["PMC8234957", "34205797"]}]}], "History": [{"Year": "2023", "Month": "12", "Day": "7"}, {"Year": "2024", "Month": "4", "Day": "3"}, {"Year": "2024", "Month": "4", "Day": "10"}, {"Year": "2024", "Month": "5", "Day": "14", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "5", "Day": "14", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "5", "Day": "14", "Hour": "3", "Minute": "42"}, {"Year": "2024", "Month": "5", "Day": "2"}], "PublicationStatus": "epublish", "ArticleIdList": ["38742068", "PMC11089324", "10.1016/j.heliyon.2024.e29559", "S2405-8440(24)05590-7"]}}]}